The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes.

Georgiou, N A; van der Bruggen, T; Jansen, C A; Oudshoorn, M; Nottet, H S; Marx, J J; van Asbeck, B S

Georgiou, N A; van der Bruggen, T; Jansen, C A; Oudshoorn, M; Nottet, H S; Marx, J J; van Asbeck, B S.

Affiliation

Georgiou NA; Department of Internal Medicine, Room F02.126, University Medical Center Utrecht, Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands.

Int J Antimicrob Agents ; 18(6): 513-8, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11738337

Subject(s)

Anti-HIV Agents/pharmacology; Antibiotics, Antineoplastic/pharmacology; Bleomycin/pharmacology; HIV-1/drug effects; Indinavir/pharmacology; Leukocytes, Mononuclear/drug effects; Ritonavir/pharmacology; Zidovudine/pharmacology; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; HIV-1/physiology; Humans; Leukocytes, Mononuclear/virology; Microbial Sensitivity Tests; Virus Replication/drug effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Bleomycin / Leukocytes, Mononuclear / Zidovudine / HIV-1 / Indinavir / Ritonavir / Anti-HIV Agents / Antibiotics, Antineoplastic Limits: Humans Language: En Journal: Int J Antimicrob Agents Year: 2001 Type: Article Affiliation country: Netherlands

Search on Google

XML

PubMed Links